Testing effectiveness (Phase 2)Looking for participantsNCT06500702
What this trial is testing
Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Who this might be right for
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi 84